Ketamine vs Stellate Ganglion Block: Comparing Newer Mental Health Treatments

Two Unconventional Approaches to Mental Health

As mental health treatment evolves beyond traditional medications and talk therapy, two distinct approaches have gained significant attention: ketamine therapy and stellate ganglion block (SGB). Both represent departures from conventional psychiatric treatment. Both have passionate advocates and growing research bases. And both are being sought by patients who have not found adequate relief through standard approaches.

But despite sometimes appearing in the same conversations, ketamine and SGB are fundamentally different treatments — different mechanisms, different targets, different evidence bases, and different patient profiles. Understanding these differences is essential for making an informed treatment decision.

What Is a Stellate Ganglion Block?

The stellate ganglion is a cluster of nerve cells (a sympathetic ganglion) located in the neck, at the level of the sixth and seventh cervical vertebrae. It is part of the sympathetic nervous system — the network responsible for the "fight or flight" response.

A stellate ganglion block involves injecting a local anesthetic (typically bupivacaine) directly into or adjacent to this nerve cluster under fluoroscopic or ultrasound guidance. The procedure takes approximately 15 to 30 minutes and is performed by an anesthesiologist, pain management specialist, or interventional radiologist.

Originally developed for pain conditions (such as complex regional pain syndrome and phantom limb pain), SGB has more recently been explored as a treatment for PTSD, anxiety, and depression. The theory is that by temporarily "resetting" the overactive sympathetic nervous system, SGB can reduce the hyperarousal and hypervigilance that characterize these conditions.

How Ketamine Works Differently

Ketamine operates on an entirely different level. Rather than targeting the peripheral nervous system, ketamine acts directly on the brain's glutamate system by modulating NMDA receptors. This triggers a cascade of neuroplastic changes — the rapid formation of new synaptic connections — that can alleviate depression, anxiety, and certain pain conditions.

For a thorough explanation of ketamine's mechanism, see our complete guide to ketamine therapy.

The distinction is important: SGB works by interrupting sympathetic nervous system overactivity (a peripheral target), while ketamine works by reshaping neural connectivity in the brain (a central target). These are complementary mechanisms, not competing ones.

Conditions Treated

Ketamine Therapy

Ketamine has the broadest evidence base for:

• Treatment-resistant depression — The strongest indication, with FDA-approved esketamine (Spravato) available
• Suicidal ideation — Rapid anti-suicidal effects, often within hours
• Anxiety disorders — Growing evidence for generalized anxiety, social anxiety, and OCD
• PTSD — Promising results in multiple clinical trials
• Chronic pain — Particularly neuropathic pain conditions
• Bipolar depression — Under careful psychiatric supervision

Stellate Ganglion Block

SGB has evidence primarily for:

• PTSD — The strongest indication, with the most robust research
• Anxiety — Particularly anxiety linked to sympathetic hyperarousal
• Hot flashes — An established non-psychiatric indication
• Complex regional pain syndrome — Its original pain indication

SGB's evidence for standalone depression treatment is currently limited. While some patients with PTSD and comorbid depression report mood improvement after SGB, this may reflect secondary benefits of reduced PTSD symptoms rather than direct antidepressant effects.

Comparing the Evidence

Research Volume and Quality

Ketamine: Hundreds of published clinical trials, multiple systematic reviews and meta-analyses, and FDA approval (as esketamine) for treatment-resistant depression. Research spans more than 25 years, with contributions from major institutions including Yale, Mount Sinai, NIH, and the VA system. The evidence base is large and growing.

SGB: Smaller but meaningful evidence base, primarily for PTSD. Key studies include a 2019 randomized controlled trial published in JAMA Psychiatry that found SGB produced significantly greater improvement in PTSD symptoms compared to sham injection. Several military and VA studies have shown promising results. However, the total volume of research is considerably smaller than for ketamine, and large-scale replication studies are still underway.

Response Rates

Ketamine for depression: Approximately 60 to 70 percent of treatment-resistant patients show significant improvement, with 30 to 40 percent achieving remission.

SGB for PTSD: Studies report response rates ranging from 50 to 75 percent for PTSD symptom reduction, though definitions of "response" vary across studies and the evidence base is still maturing.

Direct comparison is difficult because these treatments are typically studied for different conditions.

Speed of Onset

Ketamine: Effects often begin within hours of the first session. Significant improvement may be apparent within 24 to 72 hours. This rapid onset is one of ketamine's most distinctive features.

SGB: Many patients report noticeable changes within 30 minutes to a few hours after the procedure. Some describe it as an immediate reduction in baseline anxiety and hypervigilance — as though a dial was turned down. The speed can be dramatic.

Both treatments offer notably faster onset than traditional psychiatric medications, which typically require weeks to take effect.

Duration of Effects

Ketamine: Individual session effects typically last days to weeks. Sustained benefit requires ongoing treatment — an initial series followed by maintenance sessions every two to six weeks. See our treatment timeline for details.

SGB: Effects from a single injection can last weeks to months. Some patients report benefits lasting three to six months from a single treatment. Some patients require repeat injections, while others experience lasting improvement from one or two procedures.

The Treatment Experience

What a Ketamine Session Is Like

Depending on the route of administration (IV, oral, sublingual, or nasal spray), a ketamine session typically lasts 40 minutes to two hours. During the session, you will experience altered consciousness — dissociation, changes in perception, and sometimes emotional or visual experiences. You are monitored throughout and recover in the clinic or at home for one to two additional hours. You cannot drive afterward.

The experience is psychoactive and can be profound, strange, or occasionally uncomfortable. Many patients and clinicians believe the experiential component contributes to therapeutic benefit, particularly when combined with integration therapy. For detailed accounts, see what ketamine feels like.

What a Stellate Ganglion Block Is Like

SGB is a medical procedure, not a psychoactive experience. You lie on an examination table while the provider uses imaging guidance to place a needle near the stellate ganglion in your neck. The injection itself takes seconds. You may feel warmth in your face or arm, and your eyelid on the injection side may droop temporarily (Horner syndrome) — this is actually a sign that the block was placed correctly.

There is no altered consciousness, no dissociation, and no psychoactive experience. Most patients can drive themselves home within an hour (though having a companion is recommended for the first procedure). The experience is closer to receiving a dental nerve block than to taking a psychiatric medication.

Side Effects and Risks

Ketamine Side Effects

Common temporary effects include:

• Dissociation and perceptual changes (expected, not a side effect per se)
• Nausea (manageable with anti-nausea medication)
• Elevated blood pressure and heart rate
• Dizziness and fatigue
• Difficulty concentrating for several hours after treatment

Rare but serious risks include cardiovascular events in susceptible patients and potential for misuse. See our side effects guide for comprehensive information.

SGB Side Effects

Common temporary effects include:

• Horner syndrome (drooping eyelid, constricted pupil) on the injection side — resolves in hours
• Hoarseness or difficulty swallowing — typically resolves within hours
• Warmth or tingling in the face or arm
• Injection site soreness

Rare but serious risks include:

• Nerve damage
• Inadvertent injection into a blood vessel
• Pneumothorax (collapsed lung) — very rare with modern imaging guidance
• Allergic reaction to the anesthetic
• Seizure (extremely rare)

Both treatments have manageable side effect profiles when administered by qualified providers, but the types of risks are quite different — neuropsychiatric for ketamine, procedural for SGB.

Cost Comparison

Ketamine Therapy

• IV infusions: $400 to $800 per session; initial series of six sessions costs $2,400 to $4,800
• At-home oral ketamine (telehealth): $100 to $300 per month
• Spravato (esketamine): Often covered by insurance; out-of-pocket costs vary widely
• Ongoing maintenance adds recurring costs

For detailed cost information, see how much does ketamine cost.

Stellate Ganglion Block

• $500 to $2,000 per injection
• Many patients need only one to three injections total
• Total treatment cost may be lower if fewer repeat procedures are needed
• Insurance coverage varies — more commonly covered when billed as a pain procedure

SGB may have a lower total cost if a small number of injections provides lasting benefit, but this is highly individual.

Who Is a Better Candidate for Each?

Ketamine may be the better choice if:

• Your primary condition is treatment-resistant depression
• You have active suicidal ideation requiring rapid intervention
• You are interested in the psychological/experiential component of treatment
• You want a treatment with a large, well-established evidence base
• You are willing to commit to ongoing maintenance sessions
• You have chronic pain alongside mood symptoms

SGB may be the better choice if:

• Your primary condition is PTSD, especially with prominent hyperarousal symptoms
• You prefer a brief, non-psychoactive procedure
• You want a treatment that may require fewer repeat sessions
• You are uncomfortable with altered states of consciousness
• Your symptoms are primarily driven by sympathetic nervous system overactivity
• You want to explore a treatment with potentially longer-lasting effects per session

Consider Both if:

• You have PTSD with comorbid depression
• One treatment alone has provided partial but incomplete relief
• Your provider recommends a multimodal approach

It is worth noting that some providers offer both treatments, and some patients benefit from combining them. SGB may address the autonomic hyperarousal component while ketamine addresses the neuroplastic and mood components. These are not mutually exclusive options.

Finding Qualified Providers

For Ketamine Therapy

Look for providers with psychiatric or mental health expertise, proper monitoring capabilities, and experience with your specific condition. See our guides on choosing a ketamine clinic and provider credentials.

For Stellate Ganglion Block

Look for:

• Board-certified anesthesiologists or pain management specialists
• Experience specifically with SGB for psychiatric indications (not just pain)
• Use of imaging guidance (ultrasound or fluoroscopy) for needle placement
• Providers who collaborate with mental health professionals for comprehensive care

The Bottom Line

Ketamine and stellate ganglion block are both legitimate, evidence-based treatments that offer alternatives to conventional psychiatric approaches. They are not interchangeable — they work through different mechanisms, target different conditions most effectively, and provide fundamentally different treatment experiences.

If depression is your primary challenge, ketamine has the stronger evidence base. If PTSD with autonomic hyperarousal is the dominant issue, SGB deserves serious consideration. For complex presentations involving both, a combination approach may offer the most comprehensive relief.

As with any treatment decision, consult with qualified providers who can evaluate your specific situation and guide you toward the approach most likely to help.

References

• Stellate Ganglion Block for PTSD: A Randomized Clinical Trial — JAMA Psychiatry, 2019, landmark RCT demonstrating SGB efficacy for PTSD
• Efficacy of Ketamine for Treatment-Resistant Depression: A Systematic Review — Comprehensive meta-analysis of ketamine for depression
• The Stellate Ganglion Block for Psychiatric Indications — NIH review of SGB mechanisms and psychiatric applications
• Comparing Novel Treatments for PTSD — Review comparing emerging PTSD treatments including ketamine and SGB
• FDA Approval of Esketamine for Treatment-Resistant Depression — FDA documentation of ketamine-derivative approval
• Sympathetic Nervous System and Psychiatric Disorders — NIMH research on autonomic dysfunction in mental health conditions